Zentalis Pharmaceuticals
NASDAQ · ZNTL·New York, NY·Small-cap·Phase 3
Clinical-stage oncology company developing azenosertib, an oral, selective WEE1 kinase inhibitor, as a biomarker-driven therapy for Cyclin E1-positive platinum-resistant ovarian cancer. Pivotal Phase 2 DENALI Part 2 readout expected by year-end 2026 with potential for accelerated approval; confirmatory Phase 3 ASPENOVA initiating in 2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Zentalis Corporate Presentation — April 2026 | Corporate overview | April 15, 2026 | 39 |